Ntrk Fusions News Today : Breaking News, Live Updates & Top Stories | Vimarsana

An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.

Patrick fordePost conference perspectivesNon squamous diseaseRet targetedRet fusionOncogene subtypesRet fusion positive nsclcPlatinum doublet chemotherapyTargeted therapyLibretto 431Ntrk fusionsNon squamous lung cancer